Galleri in the Medicare Population

Eligibility Criteria

• * Aged ≥50 years with Medicare coverage,
• * Eligible to receive the Galleri test, based on a determination by the study investigator or designee that the test is clinically appropriate,
• * Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol), and
• * Able to comprehend and respond to questions in participant questionnaires. Comprehension level is determined by the study investigator or designee.
• * Aged ≥ 50 years with Medicare coverage,
• * Have had ≥ 1 UC visit
• * Having had a previous Galleri test not associated with this study.
• * Undergoing clinical evaluation for symptoms suspicious for cancer.
• * Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
• * Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
• * Prior/Concurrent Concomitant Therapy (Medications/Treatments):
• * Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date.
• * Adjuvant hormone therapy for cancer (i.e., for breast or prostate cancer) is not an exclusion criterion.
• * Current pregnancy
• * Individuals who will not be able to comply with the protocol procedures.
• * Individuals who are not currently registered patients at a participating center.
• * Previous or current employees or contractors of GRAIL.
• * Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
• * Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
• * Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
• * Prior/Concurrent Concomitant Therapy (Medications/Treatments):
• * Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date.
• * Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion.
• * Current pregnancy.